Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $68.7052W HIGH $92.18
Volume
2.18 M
Value Traded
188.40 M
Short % Float
10.02%
Days to Cover
8.3
-2.48%Week
-0.89%1 Month
-3.69%3 Month
+18.61%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.53 B
EPS (TTM)
3.81
P/E Ratio
22.64
Ent. Value
10.35 B
Total Shares
110.54 M
Float Shares
93.45 M
Insiders
15.46%
Institutions
99.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
HSIC Catalyst Timeline
Dated clinical, regulatory and corporate events for Henry Schein Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Henry Schein Inc
2Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How HSIC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every HSIC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BERGMAN STANLEY MFormer Director | Disposition | -50 253,279 held | $0.00 | 05/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HSIC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 1 % | 11.23 M | 134.42 K | -12.21% ( -18.69 K) |
Ownership Trends
HSIC Short Interest
Shares sold short, counted twice a month.
10.02%
Short % of Float
of tradable shares sold short
9.4M
Shares Sold Short
+4.0% vs prior count
8.3 High
Days to Cover
trading days of normal volume to buy every short share back
1.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HSIC ranks across every disease it competes in
Competitive Position is a premium feature
See how HSIC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHSIC News
-HSIC
Nov 10, 2026▲ +0.1%today
CareQuest and Henry Schein Launch the BRIDGE Health Network to Advance Dental-Medical Integration
CareQuest Institute and Henry Schein launched the BRIDGE Health Network to advance dental-medical integration. This collaboration aims to improve patient outcomes through a more cohesive healthcare approach. The initiative seeks to bridge gaps between dental and medical care systems. Stakeholders hope this network enhances overall health management strategies.
Read more →-HSIC
Nov 9, 2026Axxess Partners With Henry Schein Home Solutions to Simplify Access to Medical Supplies and Equipment for Clients
Axxess has partnered with Henry Schein Home Solutions to enhance access to medical supplies. This collaboration allows clients to order supplies directly through the Axxess platform, improving efficiency and reducing administrative tasks. The partnership also offers preferred pricing and flexible delivery options, benefiting home health and hospice providers.
Read more →-HSIC
Nov 5, 2026Henry Schein to Participate in Upcoming Investor Conferences in November and December
Henry Schein, Inc. announced its participation in two upcoming investor conferences. The Jefferies Healthcare Conference will take place on November 17, 2026, in London, followed by the Piper Sandler's Healthcare Conference on December 1, 2026, in New York. Presentations will be available via live webcast and replays on the company's website.
Read more →-HSIC
Nov 3, 2026Henry Schein Reports Strong 2026 Third Quarter and Raises FY2026 Guidance
Henry Schein reported strong financial results for Q3 2026, with GAAP diluted EPS rising 26.2% to $1.06. The company experienced 4.0% total sales growth, driven by an 8.6% increase in U.S. dental merchandise sales. Additionally, Henry Schein raised its FY2026 guidance for non-GAAP diluted EPS to between $5.50 and $5.56, reflecting robust operating performance.
Read more →-HSIC
Oct 20, 2026Henry Schein to Webcast Third Quarter 2026 Conference Call on Tuesday, November 3, 2026, at 8:00 a.m. ET
Henry Schein, Inc. will release its third quarter 2026 financial results on November 3, 2026, before the market opens. A live webcast of the earnings conference call will follow at 8:00 a.m. ET, featuring CEO Fred Lowery among the speakers. This event highlights the company's commitment to keeping investors informed.
Read more →-HSIC
Oct 8, 2026Henry Schein Announces Chief Financial Officer Leadership Transition
Henry Schein, Inc. has appointed Emmanuel Caprais as the new Senior Vice President and Chief Financial Officer, effective November 4, 2026. Caprais, who previously served at ITT, Inc., will report to CEO Frederick M. Lowery. This transition is part of a structured plan to enhance the company's financial leadership.
Read more →-HSIC
Sep 30, 2026Henry Schein Cares Marks 25 Years of Helping Health Happen®
Henry Schein Cares is celebrating its 25th anniversary, highlighting its role in enhancing global health through collaboration with various stakeholders. The program focuses on five key pillars aimed at improving healthcare access and policies. This milestone underscores the company's dedication to corporate citizenship and community health.
Read more →-HSIC
Sep 8, 2026Henry Schein to Participate in Upcoming Investor Conference in September
Henry Schein, Inc. announced its participation in the Baird Global Healthcare Conference scheduled for September 15, 2026. The event will take place at the InterContinental Hotel in New York City, where the company will present at 12:15 p.m. EDT. Interested parties can access the presentation via live webcast on the company's investor relations website.
Read more →-HSIC
Aug 4, 2026Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance
Henry Schein, Inc. reported robust financial results for the second quarter of 2026, highlighting strong sales performance and margin improvements. The company experienced accelerated internal local currency sales growth compared to the previous quarter. Additionally, Henry Schein raised its guidance for the full fiscal year 2026, indicating positive momentum across its business segments.
Read more →-HSIC
Jul 30, 2026Henry Schein Announces Leadership Transitions
Henry Schein, Inc. has announced the establishment of the Henry Schein Leadership Team (HSLT) to replace its Executive Management Committee. This new leadership structure aims to integrate the global supply chain with the distribution group, enhancing collaboration and execution of the company's strategic priorities.
Read more →-HSIC
Jul 21, 2026Henry Schein to Webcast Second Quarter 2026 Conference Call on Tuesday, August 4, 2026, at 8:00 a.m. ET
Henry Schein, Inc. will announce its second quarter 2026 financial results on August 4, 2026, prior to market opening. The company will host a live webcast of its earnings conference call at 8:00 a.m. ET, featuring CEO Fred Lowery among the speakers. This event emphasizes the company's commitment to transparency with investors.
Read more →-HSIC
Jun 30, 2026GoTu and Henry Schein Announce Strategic Partnership to Strengthen Dental Workforce Support Nationwide
GoTu Technology and Henry Schein, Inc. have announced a strategic partnership to enhance staffing solutions for dental practices facing workforce shortages. This collaboration allows dental offices to access GoTu's platform for temporary and permanent staffing needs, aiming to improve operational efficiency and patient care. The partnership reflects a commitment to support the dental ecosystem amid ongoing staffing challenges.
Read more →-HSIC
May 22, 2026Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board
Henry Schein has announced the election of William K. 'Dan' Daniel as the Independent Chairman of the Board. This leadership change is expected to guide the company in its future endeavors. The announcement reflects the company's commitment to strong governance and leadership.
Read more →-HSIC
May 14, 2026Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
Henry Schein One released its 2026 Catalyst Index, indicating that clinical performance is now the main driver of growth in dental practices. The report shows top performers achieving 75% case acceptance, significantly higher than the industry average of 45%. It challenges the notion that scale alone leads to better outcomes, emphasizing consistency in clinical care.
Read more →-HSIC
May 5, 2026Henry Schein Reports First Quarter 2026 Financial Results
Henry Schein has reported its financial results for the first quarter of 2026. The article provides an overview of the company's performance, but lacks specific details on revenue, profit, or strategic initiatives. Further analysis may be required to understand the implications of these results.
Read more →-HSIC
Apr 21, 2026Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET
Henry Schein, Inc. will release its first quarter 2026 financial results on May 5, 2026, before the market opens. A live webcast of the earnings conference call will begin at 8:00 a.m. ET, featuring CEO Frederick M. Lowery and CFO Ronald N. South. Investors can access the call via the company's investor website.
Read more →-HSIC
Feb 24, 2026HENRY SCHEIN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND INTRODUCES 2026 FINANCIAL GUIDANCE
Henry Schein, Inc. reported its fourth quarter and full year 2025 financial results, highlighting significant growth across its business segments. The company achieved a GAAP diluted EPS of $0.85, an increase from $0.74 in the same quarter last year, along with a non-GAAP EPS of $1.34. Total sales for Q4 2025 rose by 7.7% year-over-year, driven by robust performances in global equipment and specialty products. Additionally, Henry Schein introduced its financial guidance for 2026, projecting further sustained growth.
Read more →-HSIC
Jan 22, 2026Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET
Henry Schein, Inc. will release its fourth quarter 2025 financial results on February 24, 2026, before the market opens. A live webcast of the earnings conference call will begin at 8:00 a.m. ET, featuring CEO Stanley M. Bergman and CFO Ronald N. South. Investors can access the call online, with a replay available afterward.
Read more →-HSIC
Jan 12, 2026Henry Schein Names Frederick M. Lowery as Chief Executive Officer
Henry Schein, Inc. announced the appointment of Frederick M. Lowery as its new Chief Executive Officer, effective March 2, 2026. Lowery, a healthcare distribution veteran with over 20 years of experience, will succeed Stanley M. Bergman, who has served as CEO for 35 years. The transition aims to build on Henry Schein's reputation for innovation and customer service while executing its strategic plan for growth. Lowery's past leadership roles include significant positions at Thermo Fisher Scientific and other major corporations, aligning with the company's objectives moving forward.
Read more →-HSIC
Dec 23, 2025Henry Schein Provides Update on CEO Search Process
Henry Schein, Inc. is nearing the conclusion of its search for a new CEO, with plans to finalize the appointment by mid-January 2026. The Lead Director, Philip A. Laskawy, expressed satisfaction with the progress and the quality of candidates considered. Until a successor is appointed, current CEO Stanley Bergman will continue in his role, focusing on maintaining business momentum during the transition. The company operates globally, providing healthcare solutions largely to dental and medical practitioners.
Read more →About Henry Schein Inc
Headquarters135 DURYEA RD, MELVILLE, NY, 11747
BIOPHARMAWATCH ELITE
Trade the next HSIC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime